HLS Therapeutics Inc. (TSX:HLS)
Canada · Delayed Price · Currency is CAD 4.350
0.00 (0.00%)
Jun 10, 2026, 12:50 PM EST
HLS Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 55.74 | 55.5 | 56.62 | 63.07 | 61.47 | 60.01 | |
Revenue Growth (YoY) | -1.81% | -1.98% | -10.23% | 2.61% | 2.43% | 6.95% |
Cost of Revenue | 10.37 | 10.08 | 9 | 7.62 | 4.98 | 3.97 |
Gross Profit | 45.38 | 45.42 | 47.62 | 55.45 | 56.49 | 56.04 |
Selling, General & Admin | 27.51 | 27.71 | 32.59 | 33.86 | 35.58 | 32.06 |
Depreciation & Amortization Expenses | 21.99 | 21.82 | 22.72 | 31.94 | 34.4 | 30.26 |
Other Operating Expenses | 1.17 | 1.38 | -2.4 | 6.22 | 5.19 | 0.17 |
Total Operating Expenses | 50.67 | 50.9 | 52.91 | 72.02 | 75.17 | 62.49 |
Operating Income | -5.3 | -5.48 | -5.29 | -16.57 | -18.68 | -6.45 |
Interest Expense | -5.41 | -7.39 | -10.29 | -11.24 | -5.04 | -5.36 |
Total Non-Operating Income (Expense) | -5.41 | -7.39 | -10.29 | -11.24 | -5.04 | -5.36 |
Pretax Income | -10.71 | -12.88 | -15.58 | -27.8 | -23.72 | -11.81 |
Provision for Income Taxes | -0.42 | -0.45 | 4.07 | -0.27 | -0.12 | 1.31 |
Net Income | -10.29 | -12.43 | -19.66 | -27.53 | -23.6 | -13.12 |
Net Income to Common | -10.29 | -12.43 | -19.66 | -27.53 | -23.6 | -13.12 |
Shares Outstanding (Basic) | 31 | 32 | 32 | 32 | 32 | 32 |
Shares Outstanding (Diluted) | 31 | 32 | 32 | 32 | 32 | 32 |
Shares Change (YoY) | -1.27% | -0.98% | -1.31% | -0.52% | 0.77% | 1.48% |
EPS (Basic) | -0.32 | -0.39 | -0.62 | -0.85 | -0.73 | -0.41 |
EPS (Diluted) | -0.32 | -0.39 | -0.62 | -0.85 | -0.73 | -0.41 |
Free Cash Flow | 19.77 | 16.93 | 7.99 | 15.75 | 16.9 | 16.38 |
Free Cash Flow Growth | 16.81% | 111.88% | -49.28% | -6.80% | 3.14% | 76.00% |
Free Cash Flow Per Share | 0.63 | 0.54 | 0.25 | 0.49 | 0.52 | 0.51 |
Dividends Per Share | - | - | - | 0.076 | 0.148 | 0.158 |
Dividend Growth | - | - | - | -48.76% | -6.50% | 0.69% |
Gross Margin | 81.40% | 81.83% | 84.11% | 87.91% | 91.90% | 93.38% |
Operating Margin | -9.51% | -9.88% | -9.34% | -26.26% | -30.39% | -10.75% |
Profit Margin | -18.46% | -22.40% | -34.71% | -43.65% | -38.39% | -21.86% |
FCF Margin | 35.47% | 30.50% | 14.11% | 24.97% | 27.49% | 27.30% |
EBITDA | 16.69 | 16.33 | 17.43 | 15.37 | 15.72 | 23.81 |
EBITDA Margin | 29.95% | 29.43% | 30.78% | 24.37% | 25.57% | 39.68% |
EBIT | -5.3 | -5.48 | -5.29 | -16.57 | -18.68 | -6.45 |
EBIT Margin | -9.51% | -9.88% | -9.34% | -26.26% | -30.39% | -10.75% |
Effective Tax Rate | 3.92% | 3.46% | -26.14% | 0.98% | 0.52% | -11.09% |